Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 13:6:41.
doi: 10.3389/fmed.2019.00041. eCollection 2019.

Biologic Treatments in Interstitial Lung Diseases

Theodoros Karampitsakos  1 , Argyro Vraka  2 , Demosthenes Bouros  2 , Stamatis-Nick Liossis  3 , Argyris Tzouvelekis  2
Affiliations
Review

Biologic Treatments in Interstitial Lung Diseases

Theodoros Karampitsakos et al. Front Med (Lausanne). .

Abstract

Interstitial lung diseases (ILD) represent a group of heterogeneous parenchymal lung disorders with complex pathophysiology, characterized by different clinical and radiological patterns, ultimately leading to pulmonary fibrosis. A considerable proportion of these disease entities present with no effective treatment, as current therapeutic regimens only slow down disease progression, thus leaving patients, at best case, with considerable functional disability. Biologic therapies have emerged and are being investigated in patients with different forms of ILD. Unfortunately, their safety profile has raised many concerns, as evidence shows that they might cause or exacerbate ILD status in a subgroup of patients. This review article aims to summarize the current state of knowledge on their role in patients with ILD and highlight future perspectives.

Keywords: biologic treatments; interstitial lung diseases; pulmonary fibrosis; safety; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Studies investigating biologic treatments in patients with IPF.
See this image and copyright information in PMC

References

    1. Travis WD, Costabel U, Hansell DM, King TE, Jr, Lynch DA, Nicholson AG, et al. . An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Resp Critic Care Med. (2013) 188:733–48. 10.1164/rccm.201308-1483ST - DOI - PMC - PubMed
    1. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. . An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Resp Critic Care Med. (2015) 192:e3–19. 10.1164/rccm.201506-1063ST - DOI - PubMed
    1. Tzouvelekis A, Karampitsakos T, Kontou M, Granitsas A, Malliou I, Anagnostopoulos A, et al. . Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: a real-life observational study. Pulm Pharmacol Ther. (2018) 49:61–6. 10.1016/j.pupt.2018.01.006 - DOI - PubMed
    1. Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, et al. Longitudinal “real-world” outcomes of pirfenidone in idiopathic pulmonary fibrosis in greece. Front Med. (2017) 4:213 10.3389/fmed.2017.00213 - DOI - PMC - PubMed
    1. Tzouvelekis A, Ntolios P, Karampitsakos T, Tzilas V, Anevlavis S, Bouros E, et al. . Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: a real-world observational study. Pulm Pharmacol Ther. (2017) 46:48–53. 10.1016/j.pupt.2017.08.011 - DOI - PubMed

LinkOut - more resources